CalciMedica Directors Load Up on Zero‑Cost Options Amid Market Downturn—Is a Breakout Looming?
CalciMedica insiders surge buying amid 79% YTD drop—could signal a Phase II breakthrough or a risky sell‑the‑dirt run. What does this mean for investors?
3 minutes to read
